RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.4 EUR | -.--% |
|
+0.12% | -0.88% |
| 27/05 | Recordati acquires treasury shares for more than EUR3 million | AN |
| 21/05 | Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... |  |
| Sales 2024 * | 230.08Cr 249.77Cr 21TCr | Sales 2025 * | 244.01Cr 264.89Cr 22TCr | Capitalization | 995.48Cr 1.08TCr 90TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 48Cr 52Cr 4.33TCr | Net income 2025 * | 52Cr 57Cr 4.74TCr | EV / Sales 2024 * | 4.89 x |
| Net Debt 2024 * | 129.99Cr 141.12Cr 12TCr | Net Debt 2025 * | 108.29Cr 117.55Cr 9.8TCr | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
19.4
x | Employees | 4,455 |
| Yield 2024 * |
2.91% | Yield 2025 * |
3.2% | Free-Float | 46.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
| 1 week | +0.12% | ||
| 1 month | -3.59% | ||
| 3 months | -6.85% | ||
| 6 months | +9.53% | ||
| Current year | -0.88% |
1 week
47.28
48.86
1 month
47.2852.35
Current year
47.2853.40
1 year
41.7553.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.3057.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 01/21/01 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 01/19/01 |
Andrea Recordati
CHM | Chairman | 52 | 29/98/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 12/18/12 |
Giampiero Mazza
BRD | Director/Board Member | 55 | 12/18/12 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 01/21/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 48.4 | +1.98% | 673,807 |
| 30/24/30 | 47.46 | -0.50% | 183,461 |
| 29/24/29 | 47.7 | -0.83% | 181,154 |
| 28/24/28 | 48.1 | -1.19% | 176,379 |
| 27/24/27 | 48.68 | +0.70% | 161,403 |
Real-time Borsa Italiana, May 31, 2024 at 09:14 pm IST
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
48.4
EUR
Average target price
52.24
EUR
Spread / Average Target
+7.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.88% | 1.08TCr | |
| +40.73% | 74TCr | |
| +32.83% | 60TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +4.05% | 28TCr | |
| +15.00% | 24TCr | |
| +9.78% | 21TCr | |
| -5.52% | 21TCr | |
| +6.17% | 16TCr |
- Stock Market
- Equities
- REC Stock
